Seelos Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders.
Seelos Therapeutics stock last closed at $0.30, up 7.53% from the previous day, and has decreased 98.55% in one year. It has underperformed other stocks in the Biotechnology industry by 0.78 percentage points. Seelos Therapeutics stock is currently +10.7% from its 52-week low of $0.27, and -99.4% from its 52-week high of $49.80.
As of May 1, 2024, there are 13.68M shares of SEEL outstanding. The market cap of SEEL is $4.10M. In the past 24 hours, 324,983 SEEL shares were traded.
You will need a brokerage account to access the NASDAQ market and buy SEEL shares.
Based on our experience, eToro is the best place to buy stocks. Here's why:
Get $10 towards your purchase of stock by opening an account with eToro today.
Open eToro AccountNow that you've selected the right brokerage, it's time to fill out some personal details so you are able to buy SEEL stock today.
Now that you've filled out your info on the stock trading app, you can securely and quickly fund your account:
Watch the video below to see the process of transferring funds into your new brokerage account.
After you have figured out the best place to buy Seelos Therapeutics stock, it's absolutely critical to research their stock before you invest, so you actually comprehend the risk as well as the opportunity.
WallStreetZen was built to help everyday investors perform more in-depth fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on SEEL's stock page.
Investors use a variety of different financial metrics, analyses, models, and charts to gauge SEEL's fair value.
You can access more valuation research on SEEL's stock here.
You can dig deeper into what analysts are saying on the Seelos Therapeutics stock forecast page.
Last year, SEEL revenue was $2.20M. During the last 4 year, SEEL's revenue has gone up by 55.68% per year. This was faster than the Biotechnology industry average of 28.49%.
You can research SEEL's earnings and revenue performance here.
Over the past 12 months, insiders at SEEL have bought more shares than they have sold.
Michael Joseph Golembiewski, Chief Financial Officer of SEEL, was the latest SEEL insider to buy. They bought $457.45 worth of SEEL stock on Feb 29, 2024.
Get more info about who owns SEEL stock here.
No, Seelos Therapeutics doesn't provide an income stream by paying out dividends.
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to see what other traders have to say.
You have two primary options:
Click the Open Trade button and eToro will place your order.
If you need more assistance buying stocks on eToro, watch the helpful video below:
Now that you own some shares in SEEL, you'll want to stay up-to-date on your stock purchase.
Make a watchlist to keep tabs on your SEEL stock.
To summarize, here are the 6 steps to buy Seelos Therapeutics stock:
If you are looking for a brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you would like to track your new investment in Seelos Therapeutics, click below.